Cargando…
Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy
Cancer stem cells (CSCs) are the main drivers of disease progression and chemotherapy resistance in breast cancer. Tumor progression and chemoresistance might then be prevented by CSC-targeted therapies. We previously demonstrated that Toll-like Receptor (TLR)2 is overexpressed in CSCs and fuels the...
Autores principales: | Di Lorenzo, Antonino, Bolli, Elisabetta, Ruiu, Roberto, Ferrauto, Giuseppe, Di Gregorio, Enza, Avalle, Lidia, Savino, Aurora, Poggio, Pietro, Merighi, Irene Fiore, Riccardo, Federica, Brancaccio, Mara, Quaglino, Elena, Cavallo, Federica, Conti, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225225/ https://www.ncbi.nlm.nih.gov/pubmed/35756841 http://dx.doi.org/10.1080/2162402X.2022.2086752 |
Ejemplares similares
-
Toll-Like Receptor 2 at the Crossroad between Cancer Cells, the Immune System, and the Microbiota
por: Di Lorenzo, Antonino, et al.
Publicado: (2020) -
RGD_PLGA Nanoparticles with Docetaxel: A Route for Improving Drug Efficiency and Reducing Toxicity in Breast Cancer Treatment
por: Di Gregorio, Enza, et al.
Publicado: (2022) -
Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial
por: Riccardo, Federica, et al.
Publicado: (2022) -
The dark-side of the outside: how extracellular heat shock proteins promote cancer
por: Seclì, Laura, et al.
Publicado: (2021) -
Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis
por: Macagno, Marco, et al.
Publicado: (2022)